أعرض في EDS

Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer

التفاصيل البيبلوغرافية
العنوان: Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
المؤلفون: Giandomenico Roviello, Michele Aieta, Pietro Rosellini, Raffaele Conca, Valerio Nardone, Roberto Petrioli, Andrea Giovanni Multari
المساهمون: Roviello, G, Petrioli, R, Nardone, V, Rosellini, P, Multari, A G, Conca, R, Aieta, M
المصدر: Medicine. 97:e10745
بيانات النشر: Ovid Technologies (Wolters Kluwer Health), 2018.
سنة النشر: 2018
مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Phases of clinical research, docetaxel, fluorouracil, gastric cancer, human epidermal receptor-2, oxaliplatin, trastuzumab, Administration, Intravenous, Adult, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Docetaxel, Esophagogastric Junction, Female, Humans, Kaplan-Meier Estimate, Male, Neoplasm Staging, Oxaliplatin, Receptor, ErbB-2, Stomach, Adenocarcinoma, Fluorouracil, Organoplatinum Compounds, Stomach Neoplasms, Taxoids, Trastuzumab, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, In patient, Receptor, neoplasms, business.industry, Cancer, General Medicine, medicine.disease, digestive system diseases, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, therapeutics, medicine.drug
الوصف: The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.Treatment consisted of docetaxel 70 mg/m combined with oxaliplatin 130 mg/m on day 1, and continuous infusion
تدمد: 0025-7974
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ca6039b250bd3f802c660475064089Test
https://doi.org/10.1097/md.0000000000010745Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....c5ca6039b250bd3f802c660475064089
قاعدة البيانات: OpenAIRE
الوصف
تدمد:00257974